Valneva share breaks through €2.66 support and slides during session

€2.66 support broken, stock slides below its 50-day MA during session

Valneva declines 2.73% to €2.64 during the session, after breaking through its €2.66 downside support. The stock remains below this threshold, which had held during previous tests. This breach is accompanied by a decline below the 50-day MA, which is trading at €2.65, with a negative gap of 0.53%: the price is now trading below this medium-term moving average, after trading near it in recent sessions. The 20-day MA, higher at €2.83, confirms that the stock has lost ground across all its short-term moving average references.

The RSI at 47 remains neutral, without a marked oversold signal, which limits the interpretation of immediate selling exhaustion. Over the week, the decline has reached 5.38%, following yesterday's rebound which had propelled the stock among the best performers of the SBF 120. The next visible resistance is located at €2.99, representing a gap of approximately 13% above the current price.

Cautious guidance for 2026 and upcoming Lyme regulatory decision

During the publication of the first half of 2026, on August 13, 2026, Valneva had confirmed its outlook for the fiscal year, projecting revenues of around €147.5 million, in a context described as cautious. The company mentioned the negative impact of the geopolitical situation on travel, which continues to weigh on sales of IXIARO, its vaccine against Japanese encephalitis, notably deliveries to the U.S. Department of Defense whose schedule remains uncertain. Conversely, the laboratory indicated it expected, within twelve months following this publication, regulatory decisions on its candidate vaccine LB6V against Lyme disease, developed with Pfizer. This deadline constitutes a follow-up point for the group's trajectory, whose stock is still posting a decline of 46.77% over one year despite the 16.9% rebound recorded over the past three months.